^
    20h
    Targeting CD276 (B7-H3) Positive Solid Tumors by 4SCAR-276 (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Shenzhen Geno-Immune Medical Institute | Trial completion date: May 2024 --> Dec 2030 | Trial primary completion date: May 2023 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    CD276 (CD276 Molecule)
    |
    4SCAR-276